Aggregation-induced emission of 1-methyl-1, 2, 3, 4, 5-pentaphenylsilole
J Luo, Z Xie, JWY Lam, L Cheng, H Chen… - Chemical …, 2001 - pubs.rsc.org
… Jingdong Luo a , Zhiliang Xie ab , Jacky WY Lam a , Lin Cheng a , Haiying Chen b ,
Chengfeng Qiu b , Hoi Sing Kwok b , Xiaowei Zhan c , Yunqi Liu c , Daoben Zhu c and Ben …
Chengfeng Qiu b , Hoi Sing Kwok b , Xiaowei Zhan c , Yunqi Liu c , Daoben Zhu c and Ben …
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
JA Engelman, J Luo, LC Cantley - Nature Reviews Genetics, 2006 - nature.com
Phosphatidylinositol 3-kinases (PI3Ks) evolved from a single enzyme that regulates vesicle
trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metabolism …
trafficking in unicellular eukaryotes into a family of enzymes that regulate cellular metabolism …
[HTML][HTML] Clinical characteristics of 2019 novel coronavirus infection in China
…, J Wang, J Liu, Z Chen, G Li, Z Zheng, S Qiu, J Luo… - MedRxiv, 2020 - medrxiv.org
Background Since December 2019, acute respiratory disease (ARD) due to 2019 novel
coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. We …
coronavirus (2019-nCoV) emerged in Wuhan city and rapidly spread throughout China. We …
[HTML][HTML] Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis
…, Z Chen, G Li, Z Zheng, S Qiu, J Luo… - European …, 2020 - Eur Respiratory Soc
… Chin Med J 2020; in press [https://doi.org/10.1097/CM9.0000000000000744]. doi:10.1097/CM9.…
Am J Respir Crit Care Med 2019; 200: e45–e67. doi:10.1164/rccm.201908-1581ST …
Am J Respir Crit Care Med 2019; 200: e45–e67. doi:10.1164/rccm.201908-1581ST …
Drugging the undruggable RAS: Mission possible?
AD Cox, SW Fesik, AC Kimmelman, J Luo… - Nature reviews Drug …, 2014 - nature.com
Despite more than three decades of intensive effort, no effective pharmacological inhibitors
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …
of the RAS oncoproteins have reached the clinic, prompting the widely held perception that …
Mass spectrometry-based metabolomics: a guide for annotation, quantification and best reporting practices
Mass spectrometry-based metabolomics approaches can enable detection and
quantification of many thousands of metabolite features simultaneously. However, compound …
quantification of many thousands of metabolite features simultaneously. However, compound …
[HTML][HTML] Clinical characteristics of coronavirus disease 2019 in China
…, Z Chen, G Li, Z Zheng, S Qiu, J Luo… - New England journal …, 2020 - Mass Medical Soc
Background Since December 2019, when coronavirus disease 2019 (Covid-19) emerged in
Wuhan city and rapidly spread throughout China, data have been needed on the clinical …
Wuhan city and rapidly spread throughout China, data have been needed on the clinical …
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
…, X Li, L Ren, X Gu, L Kang, L Guo, M Liu, X Zhou, J Luo… - The Lancet, 2021 - thelancet.com
Background The long-term health consequences of COVID-19 remain largely unclear. The
aim of this study was to describe the long-term health consequences of patients with COVID-…
aim of this study was to describe the long-term health consequences of patients with COVID-…
GSDS 2.0: an upgraded gene feature visualization server
Visualizing genes’ structure and annotated features helps biologists to investigate their
function and evolution intuitively. The Gene Structure Display Server (GSDS) has been widely …
function and evolution intuitively. The Gene Structure Display Server (GSDS) has been widely …
[HTML][HTML] AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer
…, MA Carducci, MA Eisenberger, J Luo - … England Journal of …, 2014 - Mass Medical Soc
Background The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-binding
domain, which is the target of enzalutamide and abiraterone, but remains constitutively …
domain, which is the target of enzalutamide and abiraterone, but remains constitutively …